--- title: "Tempus AI Stock Climbs Friday: What's Driving the Move?" type: "News" locale: "en" url: "https://longbridge.com/en/news/296632946.md" description: "Tempus AI (TEM) shares rose 5.09% to $70.04 on Friday, driven by positive follow-through from Merck and Moderna's successful Phase 3 clinical trial results for a custom mRNA cancer therapy. This treatment utilizes Personalis Inc.'s genomic technology, which Tempus recently acquired for $1.5 billion. The stock is trading significantly above its moving averages with an RSI in overbought territory, suggesting potential volatility despite the bullish momentum." datetime: "2026-08-21T14:47:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296632946.md) - [en](https://longbridge.com/en/news/296632946.md) - [zh-HK](https://longbridge.com/zh-HK/news/296632946.md) generator: "portal-rs" --- # Tempus AI Stock Climbs Friday: What's Driving the Move? **Tempus AI Inc**. (NASDAQ:TEM) shares are trading higher on Friday as traders continue to digest the latest follow-through from this week’s Merck–Moderna clinical-trial headline. - Tempus AI stock is gaining positive traction. What’s pushing TEM stock higher? ## What Sparked Tempus AI’s Recent Price Action? The recent spark for TEM was Phase 3 INTerpath-001 results from **Merck & Co**. and **Moderna Inc**., where intismeran autogene (a custom mRNA neoantigen therapy) paired with Keytruda improved recurrence-free survival in resected melanoma, described as the first successful Phase 3 readout for a custom mRNA-based cancer treatment. The personalized vaccine relies on **Personalis Inc.’s** genomic tumor-profiling technology, which Moderna uses to analyze patient tissue and identify specific neoantigens for custom doses. This link directly benefits Tempus AI, which agreed to acquire Personalis for $1.5 billion last month after previously partnering with the firm on minimal residual disease tests. The acquisition hands Tempus the vital sequencing infrastructure supporting Moderna’s therapeutic program right as it achieves its major Phase 3 clinical milestone. Tempus CEO **Eric Lefkofsky** highlighted the connection on social media Wednesday, congratulating Moderna and Merck while noting Tempus’s pride in supporting the breakthrough program. > Congratulations to @moderna\_tx and @Merck on today’s positive Phase 3 results for INTerpath-001, a major milestone for melanoma treatment and the future of more personalized care. > > We are proud to partner with Moderna in support of this important program, and we’re excited to see… > > — Eric Lefkofsky (@lefkofsky) August 19, 2026 ## Critical Levels To Watch For TEM Stock TEM is extended versus its trend gauges, trading about 33% above its 20-day SMA ($51.08) and about 19.7% above its 200-day SMA ($56.75), which often raises the odds of a pause or pullback even if the bigger move stays intact. That stretch is happening while the longer-term backdrop still carries baggage from the death cross in January (50-day SMA below the 200-day SMA), a reminder that the stock can stay volatile when momentum cools. RSI is the cleaner momentum lens right now: at 71.53, it’s in overbought territory, which typically signals the move is getting "stretched" and can mean upside becomes harder to sustain without a reset. The key question for trend traders is whether any dip is shallow (bullish consolidation) or whether it starts closing the gap back toward the major moving averages. - **Key Resistance**: $76.50 — a nearby pivot area where rebounds can stall after a fast run - **Key Support**: $61.50 — a recent floor area that sits relatively close to current price and can define whether the pullback stays controlled ## TEM Stock Price Activity on Friday **TEM Price Action:** Tempus AI shares were up 5.09% at $70.04 at the time of publication on Friday, according to Benzinga Pro data. **Read Also: Abbott Bypasses Appeals Process To Settle Ongoing Premature Infant Formula Litigation** *Image: Shutterstock* ### Related Stocks - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [TEM.US](https://longbridge.com/en/quote/TEM.US.md) - [PSNL.US](https://longbridge.com/en/quote/PSNL.US.md) - [TEMT.US](https://longbridge.com/en/quote/TEMT.US.md) - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) - [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md) - [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md) - [ABT.US](https://longbridge.com/en/quote/ABT.US.md) ## Related News & Research - [Andrew Polovin Sells 22,148 Shares of Tempus AI (NASDAQ:TEM) Stock](https://longbridge.com/en/news/296610788.md) - [Tempus AI (NASDAQ:TEM) CAO Ryan Bartolucci Sells 6,175 Shares of Stock](https://longbridge.com/en/news/296562025.md) - [Tempus AI (TEM) Joins CellCarta Network, Is The Stock Still Undervalued?](https://longbridge.com/en/news/296430776.md) - ['Prepare for What's Coming,' Says Investor About Tempus AI Stock](https://longbridge.com/en/news/296388667.md) - [Tempus AI director Nadja West disposes of 3,000 common shares worth $161,700](https://longbridge.com/en/news/296265854.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**